We are pleased to welcome you to the “2nd International Conference on Automation and Artificial Intelligence” after the successful completion of the series of Artificial Intelligence 2020. The congress is scheduled to take place in the beautiful city of London, UK, on June 15-16, 2021. This Artificial Intelligence 2021 conference will provide you with an exemplary research experience and huge ideas. The perspective of the Artificial Intelligence Conference is to set up transplant research to help people understand how treatment techniques have advanced and how the field has developed in recent years. Conferenceseries proffers our immense pleasure and honour in extending you a warm invitation to attend Artificial Intelligence 2021 on June 15-16, 2021 in London, UK. It is focusing on “Innovations and Advancements in Automation and Artificial Intelligence”, to enhance and explore knowledge among Artificial Intelligence community and to establish corporations and exchanging ideas. Providing the right stage to present stimulating Keynote talks, Plenary sessions, Discussion Panels, B2B Meetings, Poster symposia, Video Presentations and Workshop Artificial Intelligence anticipates over 200 participants around the globe with path breaking subjects, discussions and presentations. This will be a splendid feasibility for the researchers, delegates and the students from Global Universities and Institutes to interact with the world class scientists, speakers, Analyst, practitioners and Industry Professionals. Conference Series invites all the experts and researchers from the Automation and Artificial Intelligence sector all over the world to attend “International Conference on Automation and Artificial Intelligence (Artificial Intelligence 2021) which is going to be held on June 15-16, 2021 in London, UK. Artificial Intelligence 2021 conference includes Keynote presentations, Oral talks, Poster Presentations, Workshops, and Exhibitors. Artificial Intelligence is a region of software engineering that emphasises the production of intelligent machines that work and respond like people. Artificial Intelligence is expert in studying how human brain thinks, learn, decide, and work while trying to solve a problem, and then using the products of this study as a source of increasing smart software and systems. In the real life, the knowledge has some undesirable properties. In the modern world, Artificial Intelligence can be used in many ways to control robots, Sensors, actuators etc., An Automation system is a system that controls and displays building organisation. These systems can be established in a few typical ways. In this segment, a general construction frame work for a structure with complex requirements due to the action such as a consulting room will be described. Actual scheme frequently have some of the features and components described here but not all of them. The Automation level consists of all progressive controls that regulate the field level devices in actual time. Online transaction is broadly utilized nowadays. This is one of the best example of Automation. In online shopping the imbursement and checkout are through online conversation system. The most other engineering majors work with Artificial Intelligence, but the heart of Artificial Intelligence is Automation and Automation Engineering across all the disciples. Artificial Intelligence 2021 conference is also comprised of Best Post Awards, Best Oral Presentation Awards, Young Researchers Forums (YRF) and also Video Presentation by experts. We are glad to welcome you all to join and register for the “International Conference on Automation and Artificial Intelligence” which is going to be held during June 15-16, 2021 at London, UK.
Statement of the Problem: Families of children who are diagnosed with pediatric cancer are at a high risk of financial toxicity, which also causes an increase in emotional distress. Families must manage childcare, travel, and food during and after their children’s treatments. The stresses of these factors on top of the tragedy of dealing with a pediatric cancer diagnosis can be devastating to the financial and emotional well-being of a family. These families require financial and emotional support during and after a child’s treatment to attempt to reduce these stresses. Researchers have reported that 1/5 of cancer patients’ families reported losing more than 40% of their annual income due to work disruptions. Financial and emotional resources for families dealing with pediatric cancer beyond research are not as common as is required considering the need that exists. Methodology & Theoretical Orientation: The mission of The Tyler Robinson Foundation is to strengthen families financially and emotionally as they cope with the tragedy of a pediatric cancer diagnosis by offsetting out-of-pocket life expenses. We have provided financial resources in the form of grants and other programs to more than 1,500 families across the world, concentrating on the United States and Canada, since our founding in 2013. Interaction between staff and families also provide much needed emotional support. Our families have let us know that the financial relief that they receive have had positive effect on their families and the amount of focus that they can place on their children. Conclusion and Significance: The Tyler Robinson Foundation has assisted families for 7 years to focus on the care of their children during pediatric cancer treatment while reducing financial stresses, which in turn provides some relief for their emotional distress. We intend to continue in our mission and expand beyond our current reach.
A bimodal pattern of hazard of relapse among early stage breast cancer patients has been identified in multiple databases from US, Europe and Asia. We are studying these data to determine if this can lead to new ideas on how to prevent relapse in breast cancer. Using computer simulation and access to a very high quality database from Milan for patients treated with mastectomy only, we proposed that relapses within 3 years of surgery are stimulated somehow by the surgical procedure. Most relapses in breast cancer are in this early category. Retrospective data from a Brussels anesthesiology group suggests a plausible mechanism. Use of ketorolac, a common NSAID analgesic used in surgery was associated with far superior disease-free survival in the first 5 years after surgery. The expected prominent early relapse events in months 9-18 are reduced 5-fold. Transient systemic inflammation accompanying surgery (identified by IL-6 in serum) could facilitate angiogenesis of dormant micrometastases, proliferation of dormant single cells, and seeding of circulating cancer stem cells (perhaps in part released from bone marrow) resulting in early relapse and could have been effectively blocked by the perioperative anti-inflammatory agent. If this observation holds up to further scrutiny, it could mean that the simple use of this safe, inexpensive and effective anti-inflammatory agent at surgery might eliminate early relapses. We suggest this would be most effective for triple negative breast cancer and be especially valuable in low and middle income countries. Similar bimodal patterns have been identified in other cancers suggesting a general effect.
The prevalence of breast cancer (BMD) in the world in general and in Ukraine is steadily increasing. Epidemiological, experimental and clinical studies have shown that metabolic disturbances associated with body mass index (BMI)> 30 kg / m2 increase the risk of occurrence and worsen the clinical course of breast cancer. Thus, in patients with obesity, a decrease in the sensitivity of the tumor to systemic antitumor therapy, an increase in the frequency of postoperative complications and a decrease in the rates of general and non-recurrent survival. The aim of the study was to improve the results of neoadjuvant systemic antitumor therapy in breast cancer patients with abdominal obesity (BMI greater than 30 kg / m2) by administering levocarnitine in combination with NSAT for the correction of metabolic disorders as the main pathogenetic part of obesity. For the study used a retrospective study between 2010 and 2014 three hundred patients (prevalence of 12.4% which is 100 thousand. population in the Dnipropetrovsk region) with BMI> 30 kg / m2, morphologically verified diagnosis of different forms of breast cancer and all stages (I- IV). Subsequently, a group of comparisons with abdominal obesity BMI> 30kg / m2 with a definite molecular subtype of tumor, levels of expression of estrogen receptor ER, progesterone PgR, Her-2 / neu, Ki-67 proliferation index was formed. The observation group of patients with breast cancer and BMI> 30kg / m2 was formed in the period from 2014 to 2018 due to prospective observation of “case-control”. Thus, the study involved 108 patients aged 32 to 76 years (mean age (58 ± 2). With nodal breast cancer II-III stage. As a result of randomization of all patients (n = 108) on breast cancer with BMI> 30 kg / m2, depending on the appointment of levocarnitine during NSAT, were divided into 2 groups: comparison and observation. In the comparison group, patients (n = 58) with BMI> 30 kg / m2 patients with breast cancer who did not receive levocarnitine during NSPT, and in the, observation group - patients (n = 50) on breast cancer with BMI> 30 kg / m2 who received levocarnitine during NIST.
An estimated 20% of all patients with cancer will develop brain metastases, with the majority of those occurring in patients with lung, breast and colorectal cancers, melanoma, and renal cell carcinoma. Brain metastases are thought to occur via seeding of circulating tumour cells into the brain microvasculature; within this unique microenvironment, tumour growth is promoted and the penetration of systemic medical therapies is limited. Development of brain metastases remains a substantial contributor to overall cancer mortality in patients with advanced-stage cancer, as prognosis remains poor despite multimodal treatments and advances in systemic therapies, which include a combination of surgery, radiotherapy, chemotherapy, immunotherapy and targeted therapies. This has driven continued development of novel immunotherapies and targeted therapies that have higher bioavailability beyond the blood–tumour barrier, to further advances in radiotherapies and minimally invasive surgical techniques. As these discoveries and innovations move from the realm of basic science to preclinical and clinical applications, future outcomes for patients with brain metastases are almost certain to improve. In this virtual presentation, we will explore combination trials in solid tumor brain metastases, highlighting the unmet needs in this patient population and underlining promising combination strategies.
Introduction: The treatment options for patients with radioactive-iodine refractory differentiated thyroid cancer include observation, multi-tyrosine kinase inhibitors (MTKIs), and traditional chemotherapy. An appropriate initial treatment with MTKI is challenging in clinical practice that the benefits outweigh the risk of any adverse events. Treatment strategies for Radioactive-Iodine Refractory Differentiated Thyroid Cancer: The activation of multiple downstream VEGFR signaling pathway, oncogenic mutated kinases (e.g. BRAF mutations), rearrangements of RET ,ALK, NTRK, and TERT promoter mutation are molecular mechanisms involved in RAI-R DTC. MTKIs demonstrated the clinical benefits either progression-free survival (11 to 18 months) or response rate (24-63%). Sorafenib and lenvatinib were approved by FDA for treatment of RAI-R DTC. However, up to 60% of patients with MTKIs required a dose reduction due to adverse events (AEs). The most frequent AEs are hypertension, diarrhea, weight loss, musocitis, fatigue,hand-foot syndrome, alopecia, and diarrhea. Therefore, close monitoring for disease progression and TSH-suppressive therapy are appropriate treatment for those patients with asymptomatic metastatic disease, or slow growing tumor. Initiation of treatment with MTKIs should be considered in symptomatic disease or rapid growing tumor. Conclusions: MTKIs demonstrate a promising approach. Sorafenib and lenvatinib have been approved by the FDA for the treatment of RAI-R DTC. However, multidisciplinary evaluation for adjustment made in order to take account of clinical benefit and risks should be performed before initiating MTKIs regarding to potential toxicities.